CD13 is a critical regulator of cell-cell fusion in osteoclastogenesis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 05 2021
24 05 2021
Historique:
received:
17
03
2021
accepted:
07
05
2021
entrez:
25
5
2021
pubmed:
26
5
2021
medline:
9
11
2021
Statut:
epublish
Résumé
The transmembrane aminopeptidase CD13 is highly expressed in cells of the myeloid lineage, regulates dynamin-dependent receptor endocytosis and recycling and is a necessary component of actin cytoskeletal organization. Here, we show that CD13-deficient mice present a low bone density phenotype with increased numbers of osteoclasts per bone surface, but display a normal distribution of osteoclast progenitor populations in the bone marrow and periphery. In addition, the bone formation and mineral apposition rates are similar between genotypes, indicating a defect in osteoclast-specific function in vivo. Lack of CD13 led to exaggerated in vitro osteoclastogenesis as indicated by significantly enhanced fusion of bone marrow-derived multinucleated osteoclasts in the presence of M-CSF and RANKL, resulting in abnormally large cells containing remarkably high numbers of nuclei. Mechanistically, while expression levels of the fusion-regulatory proteins dynamin and DC-STAMP1 must be downregulated for fusion to proceed, these are aberrantly sustained at high levels even in CD13-deficient mature multi-nucleated osteoclasts. Further, the stability of fusion-promoting proteins is maintained in the absence of CD13, implicating CD13 in protein turnover mechanisms. Together, we conclude that CD13 may regulate cell-cell fusion by controlling the expression and localization of key fusion regulatory proteins that are critical for osteoclast fusion.
Identifiants
pubmed: 34031489
doi: 10.1038/s41598-021-90271-x
pii: 10.1038/s41598-021-90271-x
pmc: PMC8144195
doi:
Substances chimiques
CD13 Antigens
EC 3.4.11.2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
10736Subventions
Organisme : NIAMS NIH HHS
ID : R01 AR055607
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR070813
Pays : United States
Organisme : NIH HHS
ID : AR070813
Pays : United States
Organisme : NIH HHS
ID : R01HL127449
Pays : United States
Références
J Immunol. 2015 May 1;194(9):4466-76
pubmed: 25801433
Dev Biol. 2007 Apr 1;304(1):317-25
pubmed: 17239847
J Cell Biol. 2014 Oct 13;207(1):73-89
pubmed: 25287300
Front Immunol. 2018 Mar 05;9:417
pubmed: 29556234
J Virol. 2017 Nov 30;91(24):
pubmed: 28978713
J Cell Biol. 2012 May 14;197(4):553-68
pubmed: 22584907
J Neurosci. 1998 Apr 15;18(8):2834-41
pubmed: 9526000
Blood. 2001 Feb 1;97(3):652-9
pubmed: 11157481
J Bone Miner Res. 2010 Jul;25(7):1468-86
pubmed: 20533309
Front Immunol. 2019 Jun 19;10:1408
pubmed: 31275328
BMC Med Genet. 2017 Nov 16;18(1):133
pubmed: 29145829
J Cell Physiol. 2010 Apr;223(1):76-83
pubmed: 20039274
J Bone Miner Res. 2012 Jan;27(1):79-92
pubmed: 21987375
J Cell Biol. 2008 Mar 10;180(5):1005-19
pubmed: 18332221
J Immunol. 2012 Jun 1;188(11):5489-99
pubmed: 22544935
J Immunol. 2015 Mar 15;194(6):2878-87
pubmed: 25694609
J Immunol. 2020 Feb 15;204(4):868-878
pubmed: 31915261
Mol Biol Cell. 2019 Aug 1;30(17):2254-2267
pubmed: 31242090
Mol Cells. 2004 Jun 30;17(3):438-45
pubmed: 15232218
Bone. 2015 Apr;73:181-9
pubmed: 25527420
Biochem Biophys Res Commun. 2015 Dec 25;468(4):611-6
pubmed: 26546825
Clin Perinatol. 2015 Jun;42(2):301-19, viii
pubmed: 26042906
Sci Signal. 2019 Apr 30;12(579):
pubmed: 31040262
Sci Rep. 2019 Jan 31;9(1):1052
pubmed: 30705363
Histol Histopathol. 2001 Apr;16(2):645-53
pubmed: 11332720
J Immunol. 2013 Oct 1;191(7):3905-12
pubmed: 23997214
J Cell Sci. 2018 Jun 5;131(11):
pubmed: 29871956
J Clin Invest. 2005 Feb;115(2):200-8
pubmed: 15690073
J Bone Miner Res. 2013 May;28(5):1203-13
pubmed: 23165930
Int J Cancer. 1993 Apr 22;54(1):137-43
pubmed: 8097496
Science. 2006 Jan 6;311(5757):83-7
pubmed: 16322423
J Bone Miner Metab. 2006;24(5):355-8
pubmed: 16937266
Nat Rev Mol Cell Biol. 2005 Jul;6(7):567-75
pubmed: 15957005
J Cell Biochem. 2013 Aug;114(8):1772-8
pubmed: 23444125
J Cell Biol. 2003 Jun 9;161(5):945-56
pubmed: 12796480
Science. 2000 Sep 1;289(5484):1504-8
pubmed: 10968780
Mol Endocrinol. 2008 Jan;22(1):176-85
pubmed: 17885208
PLoS One. 2015 Oct 22;10(10):e0141019
pubmed: 26492161
J Bone Miner Res. 2006 Jan;21(1):67-77
pubmed: 16355275
J Leukoc Biol. 2008 Aug;84(2):448-59
pubmed: 18495788
J Clin Invest. 1989 Apr;83(4):1299-307
pubmed: 2564851
Genet Mol Res. 2014 Jul 02;13(3):4776-87
pubmed: 25062413
Mol Cell Endocrinol. 2016 Sep 5;432:3-13
pubmed: 26747728
J Leukoc Biol. 2010 Aug;88(2):347-59
pubmed: 20430777
Int J Mol Sci. 2020 Aug 08;21(16):
pubmed: 32784443
J Exp Med. 1999 Dec 20;190(12):1741-54
pubmed: 10601350
Nat Rev Immunol. 2019 Oct;19(10):626-642
pubmed: 31186549
J Virol. 2004 Aug;78(16):8701-8
pubmed: 15280478
Blood. 2007 Jul 1;110(1):142-50
pubmed: 17363739
J Bone Miner Res. 2012 Jun;27(6):1289-97
pubmed: 22337159
J Exp Med. 2005 Aug 1;202(3):345-51
pubmed: 16061724
Front Physiol. 2014 Jan 09;4:402
pubmed: 24409152